Clinical Trials Directory

Trials / Sponsors / Ablynx, a Sanofi company

Ablynx, a Sanofi company

Industry · 25 registered clinical trials.

StatusTrialPhaseStarted
WithdrawnEfficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Phase 22019-02-01
TerminatedEvaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tra
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Phase 22018-03-01
CompletedCaplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.
Healthy Volunteers
Phase 12017-06-05
CompletedDose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract
Respiratory Syncytial Virus Lower Respiratory Tract Infection
Phase 22017-01-11
CompletedPhase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Acquired Thrombotic Thrombocytopenic Purpura
Phase 32015-11-01
CompletedA Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Phase 22015-07-01
CompletedAn Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumat
Rheumatoid Arthritis
Phase 22015-07-01
CompletedA Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Phase 22015-03-01
CompletedA Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Phase 22015-01-01
CompletedA Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Re
Respiratory Syncytial Virus Infection
Phase 1 / Phase 22014-12-01
CompletedBioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Healthy Volunteers
Phase 12014-07-01
CompletedALX-0061 Phase I Bioavailability Study in Healthy Volunteers
Rheumatoid Arthritis
Phase 12014-03-31
CompletedALX-0171 Safety Study in Adults With Hyperresponsive Airways
Respiratory Syncytial Virus Infection
Phase 12013-07-01
CompletedALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers
Healthy, RSV Infection
Phase 12013-05-01
CompletedALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
RSV Infection
Phase 12011-11-01
TerminatedFirst in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
Healthy Volunteers
Phase 12011-06-01
CompletedStudy Comparing The Tolerability Of Three Excipient Formulations Administered Subcutaneously To Healthy Subjec
Healthy
Phase 12011-05-01
CompletedStudy to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA
Rheumatoid Arthritis
Phase 1 / Phase 22011-03-01
CompletedStudy to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thr
Acquired Thrombotic Thrombocytopenic Purpura
Phase 22011-01-01
CompletedA Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy Subjects
Healthy
Phase 12010-10-01
CompletedStudy Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Phase 22010-02-01
CompletedStudy Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Phase 1 / Phase 22009-11-01
CompletedComparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
Phase 22009-09-01
CompletedStudy Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
Active Rheumatoid Arthritis
Phase 1 / Phase 22009-09-01
CompletedStudy Of Single Dose Of ATN-103 Administered To Healthy Japanese Male Subjects
Healthy
Phase 12008-11-01